-
MyChart
Log in to our secure, personalized website to manage your care (formerly myMDAnderson).
-
Request an Appointment
Request an Appointment
If you are ready to make an appointment, select a button on the right. If you have questions about MD Anderson’s appointment process, our information page may be the best place to start.
Appointment Information - Donate Today
MENU
Leukemia Clinical Trials
Phase I Agents for Hematologic Malignancies
- Ruxolitinib (2012-0697)
- AC220 + LD Ara-C (2012-1047)
- GSK525762 (2013-0527)
- MEDI4736 (2013-1041)
- FF-10501-01 (2014-0014)
- Ruxolitinib + DAC (2014-0344)
- OPN-305 (2014-0432)/(2017-0887)
- Bosutinib + Inotuzumab (2014-0435)
- DS-3032B (2014-0565)
- ONC201 (2014-0731)
- BGB324 (2014-0756)
- SL-401(2014-0860)
- SL-401(2014-0976)
- AMG 330 (2015-0296)
- LY2510924 + Ida + Ara-C (2015-0436)
- ADCT-402 (2015-0618)
- LY2606368 + Ara-C + Flu (2015-0665)
- AG-120 or AG-221 + 7+3 (2015-0767)
- BLU-285 (2015-0832)
- Venetoclax + Cobimetinib or Venetoclax + Idasanutlin (2015-0898)
- ADCT-402 (2015-0985)
- IMGN779 (2015-1024)
- AG-120 or AG-221 + AZA (2015-1056)
- FT-2102 (2016-0150)
- XmAb 14045 (2016-0165)
- ORH-2014 (2016-0291)
- CD33-CAR-T (2016-0341)
- H3B-8800 (2016-0547)
- INCB059872 (2016-0556)
- AMV564 (2016-0646)
- AGS62P1 (2016-0647)
- K0706 (2016-0648)
- SEL24 (2016-0713)
- Palbociclib (2016-0772)
- UCART123 in BPDCN (2016-0840)
- Venetoclax + AZA (2016-0944)
- CWP232291 + Ara-C (2016-1071)
- BAY 1251152 (2016-1114)
- DS-3201b (2016-1130)
- MGD006 (2017-0027)
- Ulocuplumab + LD Ara-C (2017-0092)
- PCM-075 + LDAC (2017-0480)
- LGH447 (2017-0592)
- AMG 176 (2017-0776)
- IMGN632 (2017-0855)
- S64315 (2017-0900)
Acute Lymphoblastic Leukemia (ALL)
Newly Diagnosed or Previously Treated
- Hyper-CVAD + Ofatumumab (2010-0708)
- Hyper-CVAD + Blinatumomab (2014-0845)
- Hyper-CVAD + INO (2015-0922)
- mHCVD + Inotuzumab +/-Blinatumomab (2010-0991)
- Venetoclax + Chemo (2016-0694)
- Hyper-CVAD + Nelarabine (2006-0328)
- Venetoclax + Chemo (2016-0694)
- Hyper-CVAD + Ponatinib (2011-0030)
- Blinatumomab + Ponatinib (2016-0792)
- Bosutinib + Inotuzumab (2014-0435)
- Hyper CVD + Ponatinib (2016-0402)
- EPOCH + Ofatumumab or Rituximab (2014-0123)
Minimal Residual Disease
Salvage Programs
- Hyper-CVAD + CMC-544 (2010-0991)
- KTE-C19 (2015-0416)
- Chemo + Blinatumomab (2017-0127)
- ADCT-402 (2015-0985)
- UCART19 (2016-0725)
- iC9/CAR (2016-0641)
- Inotuzumab (2015-0870)
- Venetoclax + Navitoclax + Chemo (2017-0679)
- Ruxolitinib or Dasatinib + HyperCVAD (2014-0521)
- ADCT-301 (2015-0618)
- EPOCH + Ofatumumab (2014-0123)
- CEC + VCR + Bortezomib (2016-0211)
- Blinatumomab + Ponatinib (2016-0792)
- Bosutinib + Inotuzumab (2014-0435)
- Hyper CVD + Ponatinib (2016-0402)
- BL-8040 + Nelarabine (2016-1101)
- Hyper-CVAD + Nelarabine (2006-0328)
Phase I/II Open to ALL
- mHCVD + Inotuzumab +/- Blinatumomab (2010-0991)
- KTE-C19 (2015-0416)
- ADCT-402 (2015-0985)
- DS-3201B (2016-1130)
- ONC201 (2014-0731)
Acute Myelogenous Leukemia (AML)
Newly Diagnosed
- Fludarabine + Ara-C + G-CSF + Gemtuzumab (2007-0147)
- ATRA and arsenic +/- Gemtuzumab (2010-0981)
- Nivolumab + Ida + Ara-C (2014-0907)
- Cladribine + Ida + Ara-C (2012-0648)
- FLAG-Ida + Venetoclax (2016-0979)
- BP1001 + LD Ara-C (2016-0128)
- Venetoclax/Placebo + LDAC (2017-0398)
- Pracinostat + AZA (2017-0173)
- Cladribine + LD Ara-C alternating DAC (2011-0987)
- Nivolumab + AZA (2014-0861)
- Venetoclax + Decitabine (2017-0912)
- Venetoxlax + AZA vs AZA (2016-0985)
- DAC (2012-1017)
- Inecalcitol + DAC (2016-0198)
- Venetoclax/Placebo + LDAC (2017-0398)
- AML123 (2017-0559)
- PCM-075 + LDAC (2017-0173)
- AG-120 or AG-221 + AZA (2015-1056)
- PDR001/MBG453 + Decitabine (2017-0256)
- SL401 + AZA (2017-0354)
- SGI-110 (2013-0843)
- Ulocuplumab + LD Ara-C (2017-0092)
FLT3 Mutated Only
IDH Mutated only
- AG-221 vs conventional care (2015-0781)
- FT-2102 (2016-0150)
- AG120 (2017-0490)
- AG-120/placebo + AZA (2017-0848)
- AG-120 or AG-221 +7 + 3 (2015-0767)
- BAY 1436032 (2016-1084)
- IDH inhibitors + AZA (2015-1056)
Frontline AML Post-Hypomethylating Therapy for MDS
Secondary Leukemia
- Ruxolitinib + DAC (2014-0344)
Mixed Phenotype Acute Leukemia
- Clofarabine, Ida, Ara-C, VCR, and Corticosteroids (2013-0073)
Salvage
FLT3 Positive at relapse
- AlloSCT Initial Salvage Therapy (2014-0358)
- AC220 + LD Ara-C (2012-1047)
- Palbociclib (2016-0772)
- CD33-CAR-T (2016-0341)
- Venetoclax + Decitabine (2017-0912)
- Cladribine + Ida + Ara-C + Sorafenib (2012-0648)
- SY-1425 (2016-0460)
- AMG 330 (2015-0296)
- XmAb 14045 (2016-0165)
- FLAG-Ida + Venetoclax (2016-0979)
- Selinexor + Sorafenib (2014-0975)
- AMG673 (2017-0365)
- PDR001/MBG453 + Decitabine (2017-0256)
- Daratumumab (2016-0889)
RAS Mutated
- AlloSCT Initial Salvage Therapy (2014-0358)
- FLAG-Ida + Venetoclax (2016-0979)
- Venetoclax + Decitabine (2017-0912)
- CD33-CAR-T (2016-0341)
- SY-1425 (2016-0460)
- AMG 330 (2015-0296)
- AMG673 (2017-0365)
- PDR001/MBG453 + Decitabine (2017-0256)
- Daratumumab (2016-0889)
AML with MLL gene at 11q23 Translocations
- SY-1425 (2016-0460)
IDH Mutated
- AG-221 vs conventional (2015-0781)
- FT-2102 (2016-0150)
- Venetoclax + Decitabine (2017-0912)
- AlloSCT Initial Salvage Therapy (2014-0358)
- CD33-CAR-T (2016-0341)
- SY-1425 (2016-0460)
- AMG 330 (2015-0296)
- XmAb 14045 (2016-0165)
- PDR001/MBG453 + Decitabine (2017-0256)
- Daratumumab (2016-0889)
- AG-120 (2017-0531)
All others (Regardless of mutation status)
- Alvocidib (Flavopiridol)/Ara-C/Mitoxantrone (FLAM) (2015-0719)
- AlloSCT Initial Salvage Therapy (2014-0358)
- CD33-CAR-T (2016-0341)
- FLAG-Ida + Venetoclax (2016-0979)
- Cladribine + Ida + Ara-C + Sorafenib (2012-0648)
- SY-1425 (2016-0460)
- Nivolumab + 5-AZA (2014-0861)
- LY2606368 + Ara-C + Flu (2015-0665)
- Venetoclax + Decitabine (2017-0912)
- DS-3032B (2014-0565)
- AMG 330 (2015-0296)
- XmAb 14045 (2016-0165)
- AML123 (2017-0559)
- ADCT-301 (2015-0618)
- Avelumab (2016-0444)
- OX40 (2017-0337)
- AMG673 (2017-0365)
- Daratumumab (2016-0889)
- IACS-010759 (2016-0250)
- SL401 + AZA (2017-0354)
- MGD006 (2017-0027)
- PDR001/MBG453 + Decitabine (2017-0256)
- SGI-110 (2016-0828)
Maintenance (Patients in CR)
Supportive Care for AML
BPDCN Treatment Priorities
Myelodysplastic Syndrome (MDS) (Includes CMML)
Specific Situations
Hypoplastic MDS and aplastic anemia
Splicing Mutations
- H3B-8800 (2016-0547)
MDS/MPN
FLT3 Positive
- AC220 + LD Ara-C (2012-1047)
RAS Mutated
- MEK162 (2013-0116)
IDH 1 Mutations
Low Risk/IPSS Int-1
- ASTX727-02 (2017-0886)
- OPN-305 (2014-0432)/(2017-0887)
- DAC vs AZA (2014-0112)
- Roxadustat/Placebo (2017-0042)
IPSS int-2 or high
- Venetoclax + AZA vs AZA Alone (2016-0757)
- Nivolumab + Ipilimumab + Aza (2014-0930)
- ASTX727-02 (2017-0886)
- SGI-110 (2013-0901)
- Pembrolizumab + AZA (2016-0343)
- CB-839 + AZA (2016-0636)
- Oral Rigosertib + AZA (2013-0030)
- Cladribine + LD Ara-C alt DAC (2011-0987)
- Cladribine + Ida + Ara-C + Sorafenib (2012-0648)
Post Hypomethylating Agents
- OPN-305 (2014-0432)
- Nivolumab + Ipilimumab + Aza (2014-0930)
- SGI-110 (2016-0587)
- Rigosertib (2015-0360)
- Pembrolizumab + AZA (2016-0343)
- Omacetaxine (2013-0870)
- Venetoclax + AZA (2016-0944)
- CB-839 + AZA (2016-0636)
- Oral Rigosertib + AZA (2013-0030)
- FF-10501-01 (2014-0014)
- Cladribine + Ida + Ara-C + Sorafenib (2012-0648)
- MEDI4736 (2013-1041)
Chronic Lymphocytic Leukemia (CLL)
CLL Immunotherapy
Untreated - early stage
- Ruxolitinib (2015-0570)
Untreated - all stages
Consolidation and Minimal Residual Disease (MRD)
- ABT-199 + Ibrutinib (2016-0785)
Prior Therapy
- Venetoclax + Ibrutinib (2015-0860)
- Lenalidomide + Obinutuzumab (2014-0115)
- CC-122 (2015-0193)
- SNS-062 – BTK-Inhibitor (2017-0158)
- Atezolizumab (2015-1097)
- BGB-3111 (2016-0396)
- XmAb®13676 (2016-0991)
- Nivolumab + Ibrutinib (2014-0931)
- iC9/CAR (2016-0641)
- JCAR017 (2017-0751)
Richter’s Transformation
Other Studies
Chronic Myelogenous Leukemia (CML)
Chronic phase
Accelerated Phase
Blastic Phase
- Axitinib + Bosutinib (2015-0787)
- BP1001 (2016-0644)
- Bosutinib + Inotuzumab (2014-0435)
- K0706 (2016-0648)
- DS-3032B (2014-0565)
Imatinib failures with T315l mutations (any stage)
Minimal Residual Disease
- Ruxolitinib (2012-0697)
Myeloproliferative Diseases
- Ruxolitinib + Thalidomide (2017-0512)
- Pacritinib (2017-0320)
- Ruxolitinib + PU-H71 (2017-0750)
- INCB050465 + Ruxolitinib (2016-0233)
- Sotatercept (ACE-011) (2012-0534)
- LCL-161 (2013-0612)
- SL-401 (2014-0976)
- Ruxolitinib + AZA (2012-0737)
- Luspatercept (ACE-536) (2017-0504)
- INCB054828 (2016-0635)
- BLU-285 (2015-0832)
- Rigosertib (2014-0546)
- Ruxolitinib vs Anagrelide (2017-0111)
Hemophagocytic Lymphohistiocytosis
- Alemtuzumab + Etoposide & Dexamethasone (2014-0989)